Inaxaplin reduces proteinuria in focal segmental glomerulosclerosis with two APOL1 variants
1. In preclinical studies, inaxaplin selectively inhibited apolipoprotein L1 (APOL1) in vitro and reduced proteinuria in a APOL1 G2-homologous transgenic ...